Analysis on Clinical Efficacy and Safety of Pioglitazone Combined with Metformin in the Treatment of Type 2 Diabetes
Wei-Ying Guo
Abstract
Wei-Ying Guo
Abstract
OBJECTIVE:To analyze clinical efficacy and safety of pioglitazone combined with metformin in the treatment of type 2 diabetes.METHODS:102 patients with type 2 diabetes were randomly divided into 2 groups.Treatment group received pioglitazone combined with metformin and treatment group received metformin alone.The levels of blood glucose and insulin were observed and compared between 2 groups.RESULTS:After 6 months of treatment,fasting plasma glucose(FPG),postprandial 2 h blood glucose(P2hBG),glycosylated hemoglobin(HbA1c),fasting insulin(FINS),postprandial 2 h insulin(P2hINS),steady-state assessment index of insulin(HOMA-IR) in 2 groups were significantly decreased,there was statistical significance in difference before and after treatment(P0.05).After treatment,the level of FPG,P2hBG,HbA1c,FINS,P2hINS and HOMA-IR in treatment group was significantly lower than in control group,there was statistical significance(P0.05);There were few adverse drug reactions,and no serious adverse drug reaction was observed.CONCLUSION:Pioglitazone combined with metformin can significantly lower the level of blood sugar and improve insulin index in patients with type 2 diabetes with few adverse drug reactions.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
OBJECTIVE:To analyze clinical efficacy and safety of pioglitazone combined with metformin in the treatment of type 2 diabetes.METHODS:102 patients with type 2 diabetes were randomly divided into 2 groups.Treatment group received pioglitazone combined with metformin and treatment group received metformin alone.The levels of blood glucose and insulin were observed and compared between 2 groups.RESULTS:After 6 months of treatment,fasting plasma glucose(FPG),postprandial 2 h blood glucose(P2hBG),glycosylated hemoglobin(HbA1c),fasting insulin(FINS),postprandial 2 h insulin(P2hINS),steady-state assessment index of insulin(HOMA-IR) in 2 groups were significantly decreased,there was statistical significance in difference before and after treatment(P0.05).After treatment,the level of FPG,P2hBG,HbA1c,FINS,P2hINS and HOMA-IR in treatment group was significantly lower than in control group,there was statistical significance(P0.05);There were few adverse drug reactions,and no serious adverse drug reaction was observed.CONCLUSION:Pioglitazone combined with metformin can significantly lower the level of blood sugar and improve insulin index in patients with type 2 diabetes with few adverse drug reactions.
Key concepts: Pioglitazone, Postprandial, Metformin, Medicine, Internal medicine, Type 2 diabetes, Insulin, Adverse effect